Objective:To investigate the impact and clinical effect of New Xuefuzhuyu soft capsule on T cell subset ratio of the patients with coronary heart disease angina.Methods:120 patients with coronary heart disease angina were randomly divided into treatment group and control group,and 60 patients were included in each group.Patients in the two groups were all treated with normal western medicine treatment.Then,the patients in treatment group were further treated with New Xuefuzhuyu soft capsule 3 times per day.4 pieces were taken for each time and the patients were treated for 28 days.Syndrome of blood stasis,clinical symptoms of Western Medicine,total cholesterol (TC),low density lipoprotein (LDL),high sensitivity-C reactive protein (hs-CRP),as well as the level of IFN-r,IL-4,and the ratio of IFN-r to IL-4 (IFN-r/IL-4) of blood serum were observed before and after treatment.Results:The total effective rate of treatment group (total curative effect) was 80.7％,which was superior to control group.The total score of angina pectoris for treatment group before and after treatment had significant and statistical difference,compared to control group.The score of blood stasis was significantly decreased.The reduction level of hs-CRP of treatment group was better than that of control group.In addition,the level of IFN-r and IFN-r/IL-4 were all decreased for treatment group,and particularly the reduction of IFN-r/IL-4 was obviously better in comparison with control group.Conclusion:New Xuefuzhuyu soft capsule is an effective compound to treat coronary disease and angina.The possible mechanism of New Xuefuzhuyu soft capsule to treat cardiovascular diseases like atherosclerosis could be the regulation of the imbalance of T cell subset ratio by dual-direction and multi-targets,and by this way,immune inflammatory reaction was reduced.%目的:探讨新血府逐瘀软胶囊对冠心病心绞痛患者T细胞亚群比例的影响及临床疗效.方法:将120例冠心病心绞痛患者随机分为治疗组、对照组各60例,2组均给予常规西药治疗,治疗组加服新血府逐瘀软胶囊,每次4粒,每天3次,治疗28 d,观察2组治疗前后血瘀证证候、西医临床症状、总胆固醇(TC)、低密度脂蛋自(LDL-C)、高敏C反应蛋白(hs-CRP)、血清IFN-r、1L-4水平及IFN-r/IL-4比值.结果:治疗组较对照组血瘀证证候积分、心绞痛总积分均降低更显著,治疗前后hs-CRP降低水平治疗组优于对照组,且治疗组IFN-r水平、IFN-r/IL-4比值较治疗前均有下降,特别是降低IFN-r/IL-4比值明显优于对照组.结论:新血府软胶囊是治疗冠心病心绞痛的有效复方,双向多靶点调节T细胞亚群比例失衡,从而减轻免疫炎症反应,可能是新血府逐瘀软胶囊治疗动脉粥样硬化性心血管疾病的作用机制之一.
展开▼
